Vpriv Market Report 2026

Vpriv Market Overview

• The Vpriv market growth in the historic period has been driven by clinical acceptance of enzyme replacement therapies, improved diagnosis of gaucher disease • Market expansion is supported by expansion of rare disease treatment access, rising investments in next-generation enzyme therapies • Growth Driver: Impact Of Rising Healthcare Spending On Rare Disease Treatments • North America was the largest region in 2025.

What Is Covered Under Vpriv Market?

Vpriv (velaglucerase alfa) is a recombinant enzyme replacement therapy developed for the long-term treatment of Gaucher disease type 1, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. It works by replacing the missing or deficient enzyme, helping to reduce the buildup of fatty substances and alleviate the symptoms associated with the disease. The main indications of the vpriv are type 1 Gaucher disease and type 3 Gaucher disease. Type 1 Gaucher disease is a rare genetic disorder caused by a deficiency in the enzyme glucocerebrosidase, which is responsible for breaking down a fatty substance called glucocerebroside. The various distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and several end users, including adults, pediatrics, and geriatrics.

What Is The Vpriv Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of rare disease treatment access, rising investments in next-generation enzyme therapies, growing demand for personalized dosing strategies, advancements in recombinant protein manufacturing, increasing focus on lifelong disease management. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on long-term rare disease management, growing use of recombinant enzyme technologies, expansion of personalized treatment regimens, enhanced emphasis on disease progression control.

Global Vpriv Market Segmentation

1) By Indication: Type 1 Gaucher Disease, Type 3 Gaucher Disease 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies 3) By End User: Adult, Pediatric, Geriatric

What Are The Drivers Of The Vpriv Market?

The rising healthcare spending is expected to propel the growth of the vpriv market going forward. Healthcare spending is driven by aging populations, advancements in medical technology, and increasing prevalence of chronic and rare diseases. Increased healthcare spending helps vpriv by enabling broader access to advanced enzyme replacement therapies, improving the affordability and availability of treatment for patients with Gaucher disease type 1, and supporting investments in diagnostic and healthcare infrastructure for rare diseases. For instance, In May 2024, according to, Office for National Statistics, UK-based Government department, Total healthcare expenditure experienced a significant rise of 5.6% in nominal terms from 2022 to 2023, marking a notable acceleration from the 0.9% growth recorded in 2022. Therefore, rising healthcare spending is driving the growth of the vpriv industry. The increased acceptance of biologics is expected to propel the growth of the vpriv market going forward. Biologics are medical products derived from living organisms, including proteins, vaccines, and gene therapies, used to treat various diseases. The increased acceptance of biologics is driven by their effectiveness in treating complex, chronic, and rare diseases with targeted, personalized therapies. Vpriv supports biologics by providing an enzyme replacement therapy specifically designed for patients with Gaucher disease type 1, exemplifying the potential of biologic treatments to address complex genetic disorders through targeted and innovative therapeutic approaches. For instance, in August 2025, according to the National Institutes of Health (NIH), a US-based government's primary agency for medical research, in 2024, the FDA approved 50 novel drugs, including 16 biologics, with six biologic approvals recorded in just the first half of the year, underscoring the strong contribution of biologics to the new drug pipeline. Therefore, increased acceptance of biologics is driving the growth of the vpriv industry. The rise in personalized medicine is expected to propel the growth of the vpriv market going forward. Personalized medicine is a medical approach that tailors treatments based on an individual's genetic makeup, lifestyle, and specific health conditions. Personalized medicine is driven by advancements in genomics, increasing precision in treatments, and the growing ability to target diseases based on individual genetic profiles. Vpriv supports personalized medicine by offering targeted enzyme replacement therapy for Gaucher disease based on individual needs. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, the rise in personalized medicine is driving the growth of the vpriv industry.

Key Players In The Global Vpriv Market

Major companies operating in the vpriv market are Takeda Pharmaceutical Company Limited

Regional Insights

North America was the largest region in the vpriv market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vpriv Market?

The vpriv market consists of sales of infusion equipment, supportive care medications, diagnostic tools, and patient monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vpriv Market Report 2026?

The vpriv market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vpriv industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.